Company Description
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases.
The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality.
It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.
The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Paul Badawi |
Contact Details
Address: 4040 Campbell Avenue, Suite 100 Menlo Park, California 94025 United States | |
| Phone | 877 266 1144 |
| Website | sightsciences.com |
Stock Details
| Ticker Symbol | SGHT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001531177 |
| CUSIP Number | 82657M105 |
| ISIN Number | US82657M1053 |
| Employer ID | 80-0625749 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Badawi | Co-Founder, President, Chief Executive Officer and Director |
| Dr. David Badawi M.D. | Co-Founder, Chief Technology Officer and Director |
| Alison Perry Bauerlein | Chief Operating Officer and Principal Operation Officer |
| Jeremy B. Hayden J.D. | Chief Legal Officer and Corporate Secretary |
| James Rodberg | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Treasurer |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics and Compliance Officer |
| Brenton Taylor | Executive Vice President of Operations and Research & Development |
| Mark Papini | Senior Vice President of Glaucoma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2025 | 144 | Filing |
| Nov 25, 2025 | 144 | Filing |
| Nov 25, 2025 | 144 | Filing |
| Nov 24, 2025 | 144 | Filing |
| Nov 21, 2025 | 144 | Filing |
| Nov 20, 2025 | 144 | Filing |
| Nov 17, 2025 | 144 | Filing |
| Nov 17, 2025 | 144 | Filing |
| Nov 14, 2025 | 144 | Filing |
| Nov 12, 2025 | 144 | Filing |